News
SVRA
5.27
-7.54%
-0.43
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf
Simply Wall St · 1d ago
LifeSci Capital Remains a Buy on Savara (SVRA)
TipRanks · 2d ago
Guggenheim Remains a Buy on Savara (SVRA)
TipRanks · 2d ago
Wells Fargo Reaffirms Their Buy Rating on Savara (SVRA)
TipRanks · 2d ago
Savara: Buy Rating Reaffirmed as MOLBREEVI Advances Toward 2026 PDUFA; $10 Price Target Maintained
TipRanks · 2d ago
Savara Says MOLBREEVI MAAs Under Review By EMA And U.K's MHRA; Decisions Expected Q1 2027 And Q4 2026, Respectively; European And Australian Patent Offices Grant MOLBREEVI Patents Until March 2041
Benzinga · 2d ago
Savara Q2 EPS $(0.16) Misses $(0.14) Estimate
Benzinga · 2d ago
Savara GAAP EPS of -$0.16 misses by $0.02
Seeking Alpha · 2d ago
Savara reports Q2 EPS (16c), consensus (15c)
TipRanks · 2d ago
Will Savara's Quarter Reveal Whether Last Time's Miss Was Pattern or Exception?
Barchart · 2d ago
Weekly Report: what happened at SVRA last week (0803-0807)?
Weekly Report · 4d ago
Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump
Seeking Alpha · 08/05 10:25
Is Savara (SVRA) Fully Priced Following Its Recent Pullback?
Simply Wall St · 08/05 04:36
Weekly Report: what happened at SVRA last week (0727-0731)?
Weekly Report · 08/03 09:19
Savara announces EPO granted a patent covering formulation of Molbreevi
TipRanks · 07/30 12:38
Weekly Report: what happened at SVRA last week (0720-0724)?
Weekly Report · 07/27 09:20
Is Savara (SVRA) Overvalued After FDA Acceptance Of Molbreevi Filing?
Simply Wall St · 07/23 06:30
Savara (SVRA) Gets a Buy from Piper Sandler
TipRanks · 07/22 11:06
Weekly Report: what happened at SVRA last week (0713-0717)?
Weekly Report · 07/20 09:20
Weekly Report: what happened at SVRA last week (0706-0710)?
Weekly Report · 07/13 09:20
More
Webull provides a variety of real-time SVRA stock news. You can receive the latest news about Savara Inc through multiple platforms. This information may help you make smarter investment decisions.
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.